Coronary stent procedures at the affiliated cardiovascular ASC in Miami-Dade

Why this matters

For decades, coronary stenting in the United States was performed exclusively in hospital cath labs, with most patients observed before discharge. In 2020, the Centers for Medicare & Medicaid Services (CMS) added PCI procedures to the ASC-payable list as part of the 2020 OPPS/ASC final rule (CMS-1717-FC), recognizing that select, well-screened patients could safely undergo coronary intervention in an outpatient setting and go home the same day.

Since 2020, ASC-based PCI has expanded across the country. Today's PCI was performed at the affiliated Kendall facility (Advanced Cardiovascular of Miami), a dedicated cardiovascular ambulatory surgery center (ASC) in Miami-Dade.

It is the result of three things coming together at the same facility:

• Cath lab access at the affiliated Kendall ASC (Advanced Cardiovascular of Miami).
• Same-day recovery infrastructure at the facility.
• A board-certified interventional cardiology team led by Dr. Pedro Martinez-Clark, with Dr. William O'Neill as Senior PI on cardiovascular research, and Dr. Hans Rutzen-Lopez on the electrophysiology side.

What this signals to clinical-trial sponsors

Beyond the clinical milestone, today's procedure is a proof point for sponsors evaluating Amavita as a cardiovascular trial site. The same combination — interventional capability, on-site recovery beds, an IRB-aware research operation — is exactly what device sponsors need for early-feasibility, first-in-human (FIH), and pivotal cardiovascular device trials.

If your team is running a cardiovascular device trial — coronary stent, drug-coated balloon, intravascular imaging, structural heart, or peripheral intervention — and you need a site that can execute the procedure under both commercial and research protocols in the same building, with same-day discharge as a routine workflow rather than an exception, we should talk.

Amavita Research holds IAOCR GCSA certification (Feb 2025). Our broader cardiovascular trial-site capabilities are documented at /capabilities and /certifications, and our sister organization bioaccess® brings 18+ years of medical-device FIH trial execution in Latin America.

About the procedure

Out of respect for patient privacy, we are not disclosing patient demographics or clinical history. The case was selected and consented under Amavita's standard interventional cardiology screening protocol. Same-day discharge was planned in advance and executed without complication.